Hutchmed

和黄医药

HCMbiotechShanghai

Trials 47

Subs 1

People 1

Links 2

Executive Summary

Hutchmed (HCM) is a Shanghai-based biotech with a diversified oncology and immunology pipeline, trading on NASDAQ and HKEX. The company has demonstrated strong deal-making capabilities with multiple partnerships including Eli Lilly, AstraZeneca, and others, positioning it as an attractive BD target. With 'clear' BIOSECURE status, Hutchmed presents minimal regulatory risk for US partnerships. Limited available corporate intelligence suggests need for deeper due diligence on current pipeline status and leadership team.

Structure: Hutchmed operates through a traditional holding company structure rather than a VIE, which simplifies due diligence and reduces structural risk for US partners. As a dual-listed entity (NASDAQ: HCM, HKEX: 13), the company maintains Western corporate governance standards and transparency requirements.

Key People

Name	Title	Education	Flags
Weiguo Su 苏慰国	CEO	PhD, Purdue University; Former VP at Pfizer

Ownership & Shareholder Structure

—

Hutchmed → Takeda

deal_partner

Takeda-HUTCHMED fruquintinib (Fruzaqla) ex-China license.

—

Hutchmed → Pfizer

personnel

Weiguo Su (HUTCHMED CEO) was former VP at Pfizer.

Subsidiaries & Affiliates(1)

Entity	Type	Jurisdiction	Scope	Flags	BIOSECURE
HUTCHMED (Shanghai) Co., Ltd. 和记黄埔医药(上海)有限公司	operating	mainland china	Drug R&D and commercial operations. Key products: surufatinib (Elunate), fruquintinib (Fruzaqla).		NONE

Corporate Events

RST

2023-11-08restructuring

FDA approves fruquintinib (Fruzaqla)

First HUTCHMED drug to gain FDA approval. Third-line CRC. Validates China-to-global drug development model. Licensed to Takeda for ex-China commercialization.

Clinical Trials(47 total)

Phase 3

Phase 2

Phase 1

Phase 2, Phase 3

Phase 1, Phase 2

NCT ID	Interventions	Phase	Status	Enrollment
NCT06601504	HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2	Ph.2	ACTIVE NOT RECRUITING	61
NCT06387082	HMPL-506	Ph.1	RECRUITING	132
NCT06361888	Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine	Ph.2, Ph.3	RECRUITING	502
NCT05930119	HMPL-453, Rabeprazole	Ph.1	COMPLETED	24
NCT05781906	HMPL-523, 150 µCi [14C]HMPL-523	Ph.1	COMPLETED	6
NCT05522231	fruquintinib+sintilimab, axitinib / everolimus, fruquintinib	Ph.2, Ph.3	ACTIVE NOT RECRUITING	265
NCT05509699	Surufatinib, Anti-PD-1/L1	Ph.2	COMPLETED	21
NCT05467943	Tazemetostat	Ph.2	COMPLETED	42
NCT05429008	HMPL-A83 injection	Ph.1	COMPLETED	40
NCT05216367	Fruquintinib	Ph.1	COMPLETED	16
NCT05368805	Fruquintinib, Dabigatran Etexilate, Rosuvastatin	Ph.1	COMPLETED	32
NCT05190068	HMPL-760	Ph.1	COMPLETED	89
NCT05093322	Surufatinib in combination with Gemcitabine	Ph.1, Ph.2	COMPLETED	13
NCT05015608	Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin	Ph.3	ACTIVE NOT RECRUITING	250
NCT05029635	HMPL-523, Placebo	Ph.3	ACTIVE NOT RECRUITING	272
NCT05015621	Surufatinib plus Toripalimab, 5-fluorouracil, Calcium folinate and Irinotecan	Ph.3	UNKNOWN	194
NCT05009836	Savolitinib, Placebo	Ph.3	ACTIVE NOT RECRUITING	320
NCT04923945	Savolitinib	Ph.3	COMPLETED	203
NCT04849351	HMPL-689	Ph.2	COMPLETED	178
NCT04762602	HMPL-306	Ph.1	TERMINATED	42

Showing 20 of 47 trials

Drug Molecules (ChEMBL)

FRUQUINTINIB

Phase 4

Small moleculeCHEMBL4303214Approved 2023

SURUFATINIB

Phase 3

Small moleculeCHEMBL4297190

Top Publications (by citations)

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

211 citationsLancet2023

Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

73 citationsCancer Discov2024

Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Jänne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE.

Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.

45 citationsEur J Cancer2023

Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, Guo J, Su W, Fan S, Tan P, Wang Y, Luo Y, Zhou H, Li J.

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.

21 citationsNat Med2024

Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Zhou F, Qin Y, Yang L, Mao W, Li Q, Dai W, Li W, Wang S, Tang Y, Ma D, Yin X, Deng Y, Yuan Y, Li M, Hu W, Chen D, Li G, Liu Q, Tan P, Fan S, Shi M, Su W, Xu RH.

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.

20 citationsCancer Commun (Lond)2023

Zhang Y, Wang ZX, Shen L, Li J, Huang J, Su WG, Zhang DS, Xu RH.

Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.

18 citationsJ Gastrointest Oncol2023

Ma S, Chen R, Duan L, Li C, Yang T, Wang J, Zhao D.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.

16 citationsMed Drug Discov2024

Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P, Pal S, Sabarwal A.

Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies.

13 citationsMolecules2024

Marques CS, Brandão P, Burke AJ.

Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.

12 citationsJ Gastrointest Oncol2023

Yang X, Yin X, Qu X, Guo G, Zeng Y, Liu W, Jagielski M, Liu Z, Zhou H.

Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.

9 citationsMil Med Res2024

Mehta K, Hegde M, Girisa S, Vishwa R, Alqahtani MS, Abbas M, Shakibaei M, Sethi G, Kunnumakkara AB.

BIOSECURE Risk

low

Company has 'clear' BIOSECURE status with no current designation concerns

Key Exposures:

•Potential future policy changes affecting China-based biotechs
•Supply chain dependencies on Chinese manufacturers

Mitigation: BIOSECURE clear status suggests company has already addressed primary regulatory concerns or operates outside scope of restrictions

BD Intelligence

Pipeline Strength6/10

Deal Readiness7/10

Therapeutic Areas:

oncologyimmunology

Recent Deals: Historical partnerships with major pharma including licensing deals, though recent activity unclear from available data

Approach: Approach with standard BD process focusing on pipeline assets and current development status. Company's clear BIOSECURE status and dual listing suggest openness to US partnerships.

Red Flags

⚠Limited publicly available corporate intelligence on current operations
⚠No recent corporate events or updates in provided data
⚠Key personnel information unavailable for relationship mapping

Quick Facts

Key People: 1
Subsidiaries: 1
CDMO/CRO Subs: 0
Genomics Subs: 0
Direct BIOSECURE: 0
Corp Events: 1
Gov-Connected: 0
Clinical Trials: 47
Publications: 10
Drug Molecules: 2
Relationships: 2

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (47 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (10 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.